EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY

ANNALS OF THE RHEUMATIC DISEASES

BMJ PUBLISHING GROUP

1. Bristol Myers Squibb